Multiplex Assay Kit for Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay)

OIF; SLRR3A; Mimecan Proteoglycan; Osteoinductive Factor

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 92-99 95
EDTA plasma(n=5) 83-99 94
heparin plasma(n=5) 96-105 101
sodium citrate plasma(n=5) 83-96 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 93-101% 88-95% 88-96% 90-102%
EDTA plasma(n=5) 78-102% 86-97% 79-91% 95-102%
heparin plasma(n=5) 95-105% 95-103% 85-101% 83-99%
sodium citrate plasma(n=5) 81-90% 91-99% 92-101% 80-104%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:OGN) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Bone. Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus. pubmed:27836731
Tohoku journal of experimental medicine Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. pubmed:28824047
Molecular Metabolism Osteoglycin, a novel coordinator of bone and glucose homeostasis Pubmed:29799418
Journal of Experimental & Clinical Cancer Research Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway Pubmed:29499765
Journal of Human Hypertension Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients Pubmed:29867136
Cell Reports Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue Pubmed: 30332637
J Clin Endocrinol Metab Osteoglycin across the adult lifespan 34850904
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPC688Hu01 Recombinant Osteoglycin (OGN) Positive Control; Immunogen; SDS-PAGE; WB.
PAC688Hu01 Polyclonal Antibody to Osteoglycin (OGN) WB; IHC; ICC; IP.
LAC688Hu71 Biotin-Linked Polyclonal Antibody to Osteoglycin (OGN) WB; IHC; ICC.
MAC688Hu22 Monoclonal Antibody to Osteoglycin (OGN) WB; IHC; ICC; IP.
SEC688Hu ELISA Kit for Osteoglycin (OGN) Enzyme-linked immunosorbent assay for Antigen Detection.
LMC688Hu Multiplex Assay Kit for Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.